- Home
- AGIO
as 07-26-2024 4:00pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Upcoming Earnings Alert:
Get ready for potential market movements as Agios Pharmaceuticals Inc. AGIO prepares to release earnings report on 01 Aug 2024.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.7B | IPO Year: | 2013 |
| Target Price: | $50.67 | AVG Volume (30 days): | 605.2K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.80 - $50.35 | Next Earning Date: | 08-01-2024 |
| Revenue: | $29,403,000 | Revenue Growth: | 54.61% |
| Revenue Growth (this year): | 69.66% | Revenue Growth (next year): | 193.64% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gheuens Sarah | AGIO | Chief Medical Officer | Jul 1 '24 | Sell | $43.85 | 3,705 | $162,464.25 | 43,736 | SEC Form 4 |
| Goff Brian | AGIO | Chief Executive Officer | Jun 5 '24 | Sell | $48.84 | 12,115 | $591,696.60 | 67,192 | SEC Form 4 |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Jun 3 '24 | Sell | $44.39 | 1,362 | $60,459.18 | 1,524 | SEC Form 4 |
| FOUSE JACQUALYN A | AGIO | Director | Apr 8 '24 | Sell | $27.55 | 7,791 | $214,642.05 | 137,396 | SEC Form 4 |
| Foster-Cheek Kaye I | AGIO | Director | Mar 7 '24 | Sell | $31.62 | 1,285 | $40,631.70 | 5,524 | SEC Form 4 |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Mar 5 '24 | Sell | $31.75 | 1,913 | $60,737.75 | 2,886 | SEC Form 4 |
| Foster-Cheek Kaye I | AGIO | Director | Mar 5 '24 | Sell | $32.21 | 300 | $9,663.00 | 11,224 | SEC Form 4 |
| Foster-Cheek Kaye I | AGIO | Director | Mar 5 '24 | Sell | $31.99 | 4,415 | $141,235.85 | 6,809 | SEC Form 4 |
| Burns James William | AGIO | Chief Legal Officer | Mar 1 '24 | Sell | $32.57 | 1,349 | $43,936.93 | 37,169 | SEC Form 4 |
| Gheuens Sarah | AGIO | Chief Medical Officer | Mar 1 '24 | Sell | $32.57 | 1,293 | $42,113.01 | 36,415 | SEC Form 4 |
| Gheuens Sarah | AGIO | Chief Medical Officer | Mar 1 '24 | Sell | $32.57 | 1,349 | $43,936.93 | 39,066 | SEC Form 4 |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Mar 1 '24 | Sell | $32.57 | 295 | $9,608.15 | 3,368 | SEC Form 4 |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Mar 1 '24 | Sell | $32.57 | 919 | $29,931.83 | 4,799 | SEC Form 4 |
| Goff Brian | AGIO | Chief Executive Officer | Mar 1 '24 | Sell | $32.57 | 4,156 | $135,360.92 | 53,780 | SEC Form 4 |
| Burns James William | AGIO | Chief Legal Officer | Mar 1 '24 | Sell | $32.57 | 1,293 | $42,113.01 | 34,518 | SEC Form 4 |
| Jones Cecilia | AGIO | Chief Financial Officer | Mar 1 '24 | Sell | $32.57 | 672 | $21,887.04 | 14,840 | SEC Form 4 |
| Schenkein David P | AGIO | Director | Feb 27 '24 | Sell | $33.60 | 11,858 | $398,428.80 | 122,854 | SEC Form 4 |
| Schenkein David P | AGIO | Director | Feb 27 '24 | Sell | $34.89 | 57,471 | $2,005,163.19 | 122,854 | SEC Form 4 |
| Schenkein David P | AGIO | Director | Feb 23 '24 | Sell | $33.05 | 47,731 | $1,577,509.55 | 122,854 | SEC Form 4 |
| Schenkein David P | AGIO | Director | Feb 23 '24 | Sell | $33.19 | 20,411 | $677,441.09 | 122,854 | SEC Form 4 |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Feb 20 '24 | Sell | $26.63 | 504 | $13,421.52 | 2,741 | SEC Form 4 |
| Gheuens Sarah | AGIO | Chief Medical Officer | Feb 12 '24 | Sell | $25.14 | 642 | $16,139.88 | 33,431 | SEC Form 4 |
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Feb 12 '24 | Sell | $25.14 | 273 | $6,863.22 | 3,245 | SEC Form 4 |
| Burns James William | AGIO | Chief Legal Officer | Feb 12 '24 | Sell | $25.14 | 545 | $13,701.30 | 31,666 | SEC Form 4 |
| Jones Cecilia | AGIO | Chief Financial Officer | Jan 20 '24 | Sell | $21.64 | 1,886 | $40,813.04 | 13,069 | SEC Form 4 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Simply Wall St.
3 days ago
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Has Found A Path To Profitability
GlobeNewswire
9 days ago
Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024
Zacks
a month ago
Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?
Simply Wall St.
a month ago
Swelling losses haven't held back gains for Agios Pharmaceuticals (NASDAQ:AGIO) shareholders since they're up 71% over 1 year
GlobeNewswire
a month ago
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
Zacks
a month ago
Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?
GuruFocus.com
2 months ago
Insider Sale: CEO Brian Goff Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.